News Wire

Insulin Prices Are Way Too High
Manufacturers Would Still Make a Good Profit If Costs Are Cut, Study Says

Blacks Too Often Left Out of Clinical Trials for Cancer Drugs
The experiments that produce “miracle” drugs do not often reflect a diverse population.

Thousands of Foster Kids Receive Psychiatric Drugs Without Safeguards
Conversely, Kids Who Need Drugs Go Untreated

New Device Will Treat Acute Coronary Artery Perforations
May Reduce the Need for Open-Heart Surgery

A Second Impurity Found in Recalled Valsartan Drug Products
NDEA, a Known Carcinogen, Discovered During FDA Testing

Lumoxiti Injection Approved for Hairy Cell Leukemia
Cleared for Adults with Relapsed or Refractory Disease

Justice Department OKs Cigna-Express Scripts Merger

Speed of approval surprises some experts, though states still have to sign off on Cigna’s $67 billion purchase of the pharmacy benefits manager.

New England Journal of Medicine Caught Up in Plagiarism Accusation Scandal
August peer-reviewed publication ignores demands that article be retracted.

Medicare Advantage Step Therapy Proposal Seen as Step Backward for Patients
Some physicians and advocacy groups argue that trying the cheaper drug first might lead to worse outcomes.

Generic Drug Companies See Their Stock Rise
Signs suggest that the companies are finally coming out of a long-running market “nightmare.”

New Dosage of Buprenorphine and Naloxone Sublingual Film
Approved as Maintenance Treatment for Opioid Dependence

Colorado’s Attorney General Sues Purdue Pharma
Says Company’s OxyContin Had “Significant Role” in Opioid Epidemic

Xofluza, Fast-Acting Flu Drug from Japan, Shows Promise in Two NEJM Studies
But Could Lead to Viral Resistance

Mood-Reading Brain Algorithm Has Potential to Treat Depression
Study Uses Experimental Software to Decode Variations in Mood

Intermountain’s Dan Liljenquist Talks About His Hopes for Civica Rx
Calls new generic drug company formed by hospital consortium a response to “untenable” circumstances.

Pages

© 2018 MediMedia, an ICON plc company. All rights reserved.